CRNX
Price
$53.17
Change
-$0.17 (-0.32%)
Updated
Jan 8, 04:59 PM (EDT)
Capitalization
5.06B
55 days until earnings call
Intraday BUY SELL Signals
RYTM
Price
$96.28
Change
-$5.31 (-5.23%)
Updated
Jan 8, 04:06 PM (EDT)
Capitalization
6.78B
55 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs RYTM

Header iconCRNX vs RYTM Comparison
Open Charts CRNX vs RYTMBanner chart's image
Crinetics Pharmaceuticals
Price$53.17
Change-$0.17 (-0.32%)
Volume$28.72K
Capitalization5.06B
Rhythm Pharmaceuticals
Price$96.28
Change-$5.31 (-5.23%)
Volume$400
Capitalization6.78B
CRNX vs RYTM Comparison Chart in %
CRNX
Daily Signal:
Gain/Loss:
RYTM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRNX vs. RYTM commentary
Jan 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and RYTM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 09, 2026
Stock price -- (CRNX: $53.34 vs. RYTM: $101.59)
Brand notoriety: CRNX and RYTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 337% vs. RYTM: 88%
Market capitalization -- CRNX: $5.06B vs. RYTM: $6.78B
CRNX [@Biotechnology] is valued at $5.06B. RYTM’s [@Biotechnology] market capitalization is $6.78B. The market cap for tickers in the [@Biotechnology] industry ranges from $122.84B to $0. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileRYTM’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • RYTM’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRNX and RYTM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while RYTM’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 4 bearish.
  • RYTM’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRNX and RYTM are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а +14.59% price change this week, while RYTM (@Biotechnology) price change was -5.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.59%. For the same industry, the average monthly price growth was +0.50%, and the average quarterly price growth was +45.26%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 04, 2026.

RYTM is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+4.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($6.78B) has a higher market cap than CRNX($5.06B). CRNX YTD gains are higher at: 14.586 vs. RYTM (-5.092). RYTM has higher annual earnings (EBITDA): -169.02M vs. CRNX (-474.16M). CRNX has more cash in the bank: 1.09B vs. RYTM (416M). RYTM has less debt than CRNX: RYTM (4.14M) vs CRNX (49.1M). RYTM has higher revenues than CRNX: RYTM (174M) vs CRNX (1.54M).
CRNXRYTMCRNX / RYTM
Capitalization5.06B6.78B75%
EBITDA-474.16M-169.02M281%
Gain YTD14.586-5.092-286%
P/E RatioN/AN/A-
Revenue1.54M174M1%
Total Cash1.09B416M263%
Total Debt49.1M4.14M1,186%
FUNDAMENTALS RATINGS
CRNX vs RYTM: Fundamental Ratings
CRNX
RYTM
OUTLOOK RATING
1..100
7369
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
4122
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4445
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RYTM's Valuation (78) in the Biotechnology industry is in the same range as CRNX (89) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew similarly to CRNX’s over the last 12 months.

RYTM's Profit vs Risk Rating (22) in the Biotechnology industry is in the same range as CRNX (41) in the Pharmaceuticals Major industry. This means that RYTM’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as RYTM (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to RYTM’s over the last 12 months.

CRNX's Price Growth Rating (44) in the Pharmaceuticals Major industry is in the same range as RYTM (45) in the Biotechnology industry. This means that CRNX’s stock grew similarly to RYTM’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as RYTM (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to RYTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXRYTM
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
74%
Bullish Trend 18 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
76%
Bearish Trend 4 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
RYTM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FKINX2.50-0.01
-0.40%
Franklin Income A1
BARUX96.52-0.65
-0.67%
Baron Asset R6
TGVNX26.73-0.21
-0.78%
TCW Relative Value Mid Cap N
HRLVX19.98-0.18
-0.89%
Harbor Large Cap Value Admin
GABPX48.44-0.63
-1.28%
Goldman Sachs Equity Income P

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+16.08%
XNCR - CRNX
59%
Loosely correlated
+6.33%
IDYA - CRNX
52%
Loosely correlated
+4.27%
RVMD - CRNX
52%
Loosely correlated
+28.63%
NUVL - CRNX
52%
Loosely correlated
+9.90%
CLDX - CRNX
51%
Loosely correlated
+5.63%
More

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with XENE. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
+2.18%
XENE - RYTM
39%
Loosely correlated
+2.73%
IDYA - RYTM
37%
Loosely correlated
+4.27%
CLDI - RYTM
36%
Loosely correlated
+0.87%
TARS - RYTM
36%
Loosely correlated
-2.25%
CRNX - RYTM
35%
Loosely correlated
+16.08%
More